Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 3/20 | 0.56 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 3/20 | 0.46 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.44 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 4/20 | 0.44 |
| ▸ | RAB9A | P51151 | 4/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL507782 | 0.84 | NOTUM (0.72) | NOTUMSIRT2CYP1A2CYP2C19CYP3A4 | |
| SCHEMBL12617891 | 0.82 | NOTUM (0.64) | NOTUMCYP1A2CYP2C19CYP2D6TSHR | |
| SCHEMBL25916014 | 0.82 | NOTUM (0.51) | NOTUMSIRT2CYP1A2CYP2C19CYP2D6 | |
| SCHEMBL2107628 | 0.82 | NPC1 (0.64) | NOTUMSIRT2NPC1RAB9AHTT | |
| SCHEMBL10904042 | 0.82 | SMN1; SMN2 (0.59) | TSHRNPC1RAB9AHTTSMN1; SMN2 | |
| SCHEMBL10937283 | 0.82 | SIRT2 (0.71) | NOTUMSIRT2CYP1A2TSHRNPC1 | |
| SCHEMBL5311162 | 0.82 | ACACB (0.59) | NOTUMCYP1A2CYP2C19CYP3A4CYP2D6 | |
| SCHEMBL26009685 | 0.82 | NOTUM (0.56) | NOTUMSIRT2CYP1A2CYP2C19CYP3A4 | |
| SCHEMBL655414 | 0.81 | NOTUM (0.68) | NOTUMCYP1A2CYP2C19CYP2D6TSHR | |
| SCHEMBL5312911 | 0.81 | MAPK1 (0.57) | NOTUMSIRT2TSHRNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260048064-A1 | AMORPHOUS SOLID DISPERSIONS COMPRISING NAPORAFENIB | NOVARTIS AG (CH) | 2026-02-19 | — | — | US | claimed |
| US-11234939-B2 | Dosage forms comprising a plasma kallikrein inhibitor | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-02-01 | — | — | US | claimed |
| US-20220023372-A1 | USE OF COCCULUS HIRSUTUS EXTRACT FOR TREATING DENGUE | SUN PHARMACEUTICAL INDUSTRIES LIMITED (IN) | 2022-01-27 | — | — | US | claimed |
| US-12629369-B2 | Pharmaceutical compositions of nilotinib | AZURITY PHARMACEUTICALS, INC. (US) | 2026-05-19 | — | — | US | disclosed |
| EP-4735631-A2 | CELL-FREE REPLICATION OF A NUCLEIC ACID CONSTRUCT | Novel Biotechnology USA Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-20260076912-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2026-03-19 | — | — | US | disclosed |
| US-20260062462-A1 | Compositions and Methods for the Prevention and Treatment of Orthopoxvirus Infections | BIOFACTURA INC (US) | 2026-03-05 | — | — | US | disclosed |
| US-20260048064-A1 | AMORPHOUS SOLID DISPERSIONS COMPRISING NAPORAFENIB | NOVARTIS AG (CH) | 2026-02-19 | — | — | US | disclosed |
| EP-4168011-B1 | ORAL FORMULATIONS AND USES THEREOF | INVENTISBIO CO LTD (CN) | 2025-11-12 | — | — | EP | disclosed |
| US-20250332165-A1 | PHARMACEUTICAL COMPOSITIONS OF NILOTINIB | AZURITY PHARMACEUTICALS, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| WO-2025215658-A1 | PHARMACEUTICAL COMPOSITIONS OF KETOTIFEN | Prabakaran Desomayanandam (IN) | 2025-10-16 | — | — | WO | disclosed |
| US-8088791-B2 | Antibacterial agents | Biots Scientific Management Pty Ltd (AU) | 2012-01-03 | — | — | US | disclosed |
| US-8088791-B2 | Antibacterial agents | Biots Scientific Management Pty Ltd (AU) | 2012-01-03 | — | — | US | disclosed |
| EP-1996180-B1 | BENZAMIDE AND PYRIDYLAMIDE DERIVATIVES AS ANTIBACTERIAL AGENTS | BIOTA EUROPE LTD (GB) | 2011-08-03 | — | — | EP | disclosed |
| EP-1996180-B1 | BENZAMIDE AND PYRIDYLAMIDE DERIVATIVES AS ANTIBACTERIAL AGENTS | BIOTA EUROPE LTD (GB) | 2011-08-03 | — | — | EP | disclosed |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2010-07-08 | — | — | US | disclosed |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2010-07-08 | — | — | US | disclosed |
| EP-1996180-A1 | ANTIBACTERIAL AGENTS | Prolysis Limited (GB) | 2008-12-03 | — | — | EP | disclosed |
| WO-2007107758-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2007-09-27 | — | — | WO | disclosed |
| WO-2007107758-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12629369-B2 | Pharmaceutical compositions of nilotinib | CSNK1D, PPARD, TP53 | NOTUM 2330/4885SIRT2 1744/4885CYP1A2 1917/4885 |
| US-20260048064-A1 | AMORPHOUS SOLID DISPERSIONS COMPRISING NAPORAFENIB | SCN2B, SLC28A2, NAPRT | NOTUM 2762/4885SIRT2 517/4885CYP1A2 142/4885 |
| US-20260062462-A1 | Compositions and Methods for the Prevention and Treatment of Orthopoxvirus Infections | IGLV6-57, VAC14, MLX | NOTUM 4769/4885SIRT2 4702/4885CYP1A2 3959/4885 |
| US-20100173933-A1 | ANTIBACTERIAL AGENTS | ALK, ROS1, NOX1 | NOTUM 3566/4885SIRT2 2237/4885CYP1A2 383/4885 |
| US-20260076912-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS | HTR4, HTR6, HTR1D | NOTUM 2328/4885SIRT2 2514/4885CYP1A2 925/4885 |
| US-11234939-B2 | Dosage forms comprising a plasma kallikrein inhibitor | KLKB1, KLK1, KLK5 | NOTUM 1088/4885SIRT2 1443/4885CYP1A2 330/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.